Fraser Dove International

👇 𝐓𝐡𝐞𝐬𝐞 𝐚𝐫𝐞 𝐲𝐨𝐮𝐫 𝐭𝐨𝐩 𝟓 𝐧𝐞𝐰𝐬 𝐬𝐭𝐨𝐫𝐢𝐞𝐬 𝐚𝐫𝐨𝐮𝐧𝐝 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐀𝐜𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐲𝐨𝐮 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐝 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤 👇 1️⃣ eXmoor Pharma's Cell & Gene Therapy Centre in Bristol has received a Manufacturing and Import Authorisation for Investigational Medicinal Products (MIA(IMP)) from the UK’s MHRA. This licence allows the facility to produce GMP-grade cell and gene therapy materials for clinical trials, marking a significant milestone in the company's expansion from consultancy to a full-service global CDMO. 📰 https://lnkd.in/evqzKv6G 2️⃣ Galderma has received FDA approval for Nemluvio, an antibody drug designed to treat prurigo nodularis, a chronic skin condition marked by severe itching and skin nodules. Nemluvio, administered via subcutaneous injection, blocks the IL-31 cytokine to reduce symptoms. 📰 https://lnkd.in/gf46vt7F 3️⃣ The FDA has approved Ascendis Pharma’s drug Yorvipath, a prodrug formulation of parathyroid hormone, for treating hypoparathyroidism in adults. This approval follows an earlier rejection due to manufacturing issues, which Ascendis addressed in a resubmitted application. 📰 https://lnkd.in/er4pggY7 4️⃣ The FDA has accepted Bristol Myers Squibb's supplemental biologics licence application (sBLA) for the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for unresectable hepatocellular carcinoma (HCC). 📰 https://lnkd.in/e6efxZaF 5️⃣ Innovent Biologics’ drug Dupert (fulzerasib) has been approved by China’s National Medical Products Administration for treating advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. 📰 https://lnkd.in/eM2F2EKF #RegulatoryActionsAndApprovals #LifeSciences #NewsRoundUp

❌ 𝐈𝐧𝐯𝐞𝐬𝐭𝐢𝐧𝐠 𝐡𝐞𝐚𝐯𝐢𝐥𝐲 𝐢𝐧 𝐞𝐦𝐩𝐥𝐨𝐲𝐞𝐫 𝐛𝐫𝐚𝐧𝐝𝐢𝐧𝐠 𝐛𝐮𝐭 𝐧𝐨𝐭 𝐬𝐞𝐞𝐢𝐧𝐠 𝐭𝐡𝐞 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐲𝐨𝐮 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝? ❌ If you're not leveraging the authentic voices of your leaders, you're not appealing to leaders. Period. Today, senior-level candidates are increasingly choosing leaders over companies. Placing your leaders at the forefront of your employer branding efforts is pivotal to success 🌟 Our expert eGuide, tailored for C-Suite and HR professionals in the life sciences, offers in-depth strategies for building a robust Digital Hiring Identity around your leadership that hooks A-players. 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐨𝐮𝐫 𝐞𝐆𝐮𝐢𝐝𝐞 𝐭𝐨𝐝𝐚𝐲 𝐚𝐧𝐝 𝐬𝐭𝐚𝐫𝐭 𝐚𝐭𝐭𝐫𝐚𝐜𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐥𝐞𝐚𝐝𝐞𝐫𝐬 𝐰𝐡𝐨 𝐰𝐢𝐥𝐥 𝐝𝐫𝐢𝐯𝐞 𝐲𝐨𝐮𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐲'𝐬 𝐬𝐮𝐜𝐜𝐞𝐬𝐬! 👇 https://lnkd.in/e4xbbWYd

👩 𝐇𝐮𝐦𝐚𝐧 𝐑𝐞𝐬𝐨𝐮𝐫𝐜𝐞𝐬 – 𝐈𝐧 𝐩𝐥𝐚𝐜𝐞 𝐭𝐨 𝐞𝐦𝐩𝐨𝐰𝐞𝐫 𝐭𝐡𝐞… 𝐡𝐮𝐦𝐚𝐧𝐬, 𝐫𝐢𝐠𝐡𝐭? 𝐍𝐨𝐭 𝐚𝐥𝐰𝐚𝐲𝐬 👨 Our CCO and LinkedIn Top Voice, Andrew MacAskill, shares his thoughts and knowledge around companies mistreating their staff. He goes on to explain that this sort of behaviour will not only bring employees down but will also damage employer branding as a biproduct. 👇 𝐓𝐨 𝐫𝐞𝐚𝐝 𝐡𝐢𝐬 𝐟𝐮𝐥𝐥 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐜𝐡𝐞𝐜𝐤 𝐨𝐮𝐭 𝐡𝐢𝐬 𝐩𝐨𝐬𝐭 𝐛𝐞𝐥𝐨𝐰 👇

“𝐑𝐞𝐬𝐩𝐞𝐜𝐭𝐟𝐮𝐥, 𝐭𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐭 𝐚𝐧𝐝 𝐭𝐫𝐮𝐬𝐭𝐰𝐨𝐫𝐭𝐡𝐲 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐰𝐨𝐫𝐝𝐬 𝐭𝐡𝐚𝐭 𝐜𝐨𝐦𝐞 𝐭𝐨 𝐦𝐢𝐧𝐝”. ✅ Richard Dane being a true asset to both client and candidate ✅ That’s another one for Fraser Dove 👏 #ExecutiveSearch #LifeSciences #FraserDove #Testimonial

1️⃣ 𝐀𝐫𝐞 𝐲𝐨𝐮 𝐥𝐨𝐨𝐤𝐢𝐧𝐠 𝐟𝐨𝐫 𝐚 𝐫𝐨𝐥𝐞 𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐚𝐫𝐨𝐮𝐧𝐝 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲? 2️⃣ 𝐀𝐫𝐞 𝐲𝐨𝐮 𝐩𝐚𝐬𝐬𝐢𝐨𝐧𝐚𝐭𝐞 𝐚𝐛𝐨𝐮𝐭 𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐟𝐨𝐫 𝐚𝐧 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐝𝐫𝐢𝐯𝐢𝐧𝐠, 𝐠𝐥𝐨𝐛𝐚𝐥 𝐩𝐡𝐚𝐫𝐦𝐚 𝐜𝐨𝐦𝐩𝐚𝐧𝐲? 3️⃣ 𝐃𝐨 𝐲𝐨𝐮 𝐰𝐚𝐧𝐭 𝐭𝐨 𝐰𝐨𝐫𝐤 𝐢𝐧 𝐚 𝐭𝐫𝐮𝐥𝐲 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐯𝐞 𝐭𝐞𝐚𝐦? ✅ A resounding, yes? This role could be your next challenge ✅ Fraser Dove International is working exclusively with a global pharma organisation who are developing treatments across respiratory, dermatology and oncology therapeutic areas. As 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐌𝐚𝐧𝐚𝐠𝐞𝐫, you will be responsible for all aspects of the Netherlands Regulatory Strategy for assigned development and marketed products. You will also be a critical member of the Global Regulatory Team (GRT) providing European-focused product strategy, European regulatory framework knowledge, and awareness of external regulatory initiatives. 𝐅𝐢𝐭 𝐭𝐡𝐞 𝐛𝐢𝐥𝐥? 𝐀𝐩𝐩𝐥𝐲 𝐭𝐨𝐝𝐚𝐲 𝐯𝐢𝐚 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤 𝐛𝐞𝐥𝐨𝐰 👇 https://lnkd.in/ecQy9CtS Alternatively, contact Peter Vedde for more information on this and similar opportunities with life science organisations in America, Asia, and Europe. #RegulatoryStrategyManager #LifeSciences #FraserDove #RoleOfTheWeek  

🌟 𝐀 𝐭𝐢𝐦𝐞 𝐨𝐟 𝐭𝐮𝐫𝐦𝐨𝐢𝐥 𝐟𝐨𝐫 𝐭𝐚𝐥𝐞𝐧𝐭 – 𝐁𝐮𝐭 𝐰𝐡𝐚𝐭’𝐬 𝐭𝐡𝐞 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧? 🌟 Our Co-Founder, Thomas Dove, outlines how challenging it is to hire the right talent for leadership roles in today’s market. He goes on to explain that 𝐓𝐚𝐥𝐞𝐧𝐭 𝐌𝐚𝐩𝐩𝐢𝐧𝐠 may not only be the answer, but also the more cost-effective option. 👇 𝐓𝐚𝐤𝐞 𝐚 𝐥𝐨𝐨𝐤 𝐚𝐭 𝐡𝐢𝐬 𝐩𝐨𝐬𝐭 𝐛𝐞𝐥𝐨𝐰 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 👇

🔄 𝐃𝐢𝐝 𝐲𝐨𝐮 𝐦𝐚𝐧𝐚𝐠𝐞 𝐭𝐨 𝐜𝐚𝐭𝐜𝐡 𝐃𝐚𝐯𝐢𝐝𝐞 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭-𝐭𝐢𝐦𝐞 𝐫𝐨𝐮𝐧𝐝? 🔄 Hosted by our CCO and LinkedIn Top Voice, Andrew MacAskill, the Exceptional Leaders podcast celebrates leaders at the forefront of the life science industry. We were thrilled to welcome Davide Pagliaro , Vice President and General Manager of EMEA at Xylox Tonbridge, to share his experiences with us and offer some valuable leadership advice. 🎙️ Tune in to learn more about: 👉 𝐗𝐲𝐥𝐨𝐱 𝐓𝐨𝐧𝐛𝐫𝐢𝐝𝐠𝐞'𝐬 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐚𝐧𝐝 𝐠𝐫𝐨𝐰𝐭𝐡 𝐚𝐦𝐛𝐢𝐭𝐢𝐨𝐧𝐬 👉 𝐓𝐡𝐞 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐜𝐞 𝐨𝐟 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 𝐫𝐞𝐚𝐥-𝐰𝐨𝐫𝐥𝐝 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐦𝐚𝐫𝐤𝐞𝐭𝐢𝐧𝐠 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 👉 𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐭𝐫𝐮𝐬𝐭 𝐚𝐧𝐝 𝐟𝐨𝐬𝐭𝐞𝐫𝐢𝐧𝐠 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐞𝐚𝐦𝐬 Listen to the full Podcast via the link below 👇 https://lnkd.in/ebH4r7WE

👇 𝐓𝐡𝐞𝐬𝐞 𝐚𝐫𝐞 𝐲𝐨𝐮𝐫 𝐭𝐨𝐩 𝟓 𝐧𝐞𝐰𝐬 𝐬𝐭𝐨𝐫𝐢𝐞𝐬 𝐚𝐫𝐨𝐮𝐧𝐝 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐲𝐨𝐮 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐝 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤 👇 1️⃣ Novo Holdings, a leading life science investor, has invested £50 million in Oxford Nanopore Technologies, a UK-based company known for its advanced molecular sensing technology. The investment highlights confidence in Oxford Nanopore’s potential in the biopharmaceutical sector. 📰 https://lnkd.in/eEpFY6ep 2️⃣ GSK and Flagship Pioneering have announced a collaboration, committing $150 million to explore potential respiratory and immunology programs. This partnership aims to develop up to 10 novel medicines and vaccines, with GSK holding exclusive rights for further development. The deal could result in up to $7.2 billion in milestone payments if all programs succeed, although this is unlikely given the high failure rate in drug development. 📰 https://lnkd.in/eWm3Eztt 3️⃣ Roche, through its Genentech arm, has licensed Sangamo Therapeutics’ gene repression technology targeting the tau protein, believed to be a key driver of Alzheimer’s disease. The deal, valued at nearly $2 billion, includes $50 million upfront with the potential for significant milestone payments. This collaboration focuses on developing genomic medicines for neurodegenerative diseases, leveraging Sangamo’s zinc finger molecules and novel delivery methods to overcome challenges in treating brain conditions. 📰 https://lnkd.in/eNQYWtK9 4️⃣ Jade Biosciences, a biotech company focused on developing therapies for autoimmune diseases, secured $80 million in funding. The investment will support the development of targeted biologics aimed at unmet medical needs in inflammation and immunology. 📰 https://lnkd.in/eF9xya2k 5️⃣ NorthStar Medical Radioisotopes and Convergent Therapeutics have expanded their collaboration for CONV01-α, a prostate cancer therapy. This partnership involves NorthStar providing high-purity Ac-225, a key component in the treatment, and manufacturing the drug for clinical trials. 📰 https://lnkd.in/eRJgw7SP #FinancialDevelopments #LifeSciences #NewsRoundUp

🔄 𝐈𝐧 𝐜𝐚𝐬𝐞 𝐲𝐨𝐮 𝐦𝐢𝐬𝐬𝐞𝐝 𝐢𝐭, 𝐰𝐞'𝐫𝐞 𝐨𝐧 𝐭𝐡𝐞 𝐥𝐨𝐨𝐤𝐨𝐮𝐭 𝐟𝐨𝐫 𝐚 𝐕𝐢𝐜𝐞 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 𝐨𝐟 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 🔄   If you excel at developing integration plans, building relationships, and creating compelling selling propositions, this role could be for you.   ✅ Feel right? Bookmark and apply for this role over the weekend via the link below or get in touch with James Stevens for more information 👇 https://lnkd.in/esebfjnd #VicePresidentOfCorporateDevelopment | #LifeSciences | #InCaseYouMissedIt

🚨 𝐈𝐭’𝐬 𝐧𝐞𝐚𝐫𝐥𝐲 𝐭𝐢𝐦𝐞 🚨   Only 𝟏 𝐃𝐀𝐘 to go until the next 𝐈𝐧𝐬𝐢𝐝𝐞 𝐌𝐞𝐝𝐓𝐞𝐜𝐡 Live Broadcast, hosted by Iain McCulley!   In this week’s episode, we welcome Jeannette Bankes, Group President, Global Franchises at Alcon. Jeannette will be speaking to us about the power of an enterprise mindset, the importance of EQ and the acceleration of digital technology.   👇 𝐉𝐨𝐢𝐧 𝐭𝐡𝐞 𝐅𝐑𝐄𝐄 𝐢𝐧𝐭𝐞𝐫𝐚𝐜𝐭𝐢𝐯𝐞 𝐞𝐯𝐞𝐧𝐭 𝐯𝐢𝐚 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤 𝐛𝐞𝐥𝐨𝐰 𝐨𝐧 𝐅𝐫𝐢𝐝𝐚𝐲 𝐭𝐡𝐞 𝟏𝟔𝐭𝐡 𝐨𝐟 𝐀𝐮𝐠𝐮𝐬𝐭 𝐚𝐭 𝟏𝟔:𝟎𝟎 𝐁𝐒𝐓 👇 https://lnkd.in/eEFRbaGq